



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

MAY 11 2001

Re: TNKase  
Docket No. 01E-0098

The Honorable Q. Todd Dickinson  
Director of U.S. Patent and Trademark Office  
Commissioner for Patents  
Box Pat. Ext.  
Washington, D.C. 20231

Dear Director Dickinson:

This is in regard to the application for patent term extension for U.S. Patent No. 5,385,732 filed by Genetech, Inc. under 35 U.S.C. § 156. The human biological product claimed by the patent is TNKase (tenecteplase), which was assigned product license application (BLA) No. 99-0903.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in *Glaxo Operations UK Ltd. v. Quigg*, 706 F. Supp. 1224 (E.D. Va. 1989), *aff'd*, 894 F. 2d 392 (Fed. Cir. 1990).

The BLA was approved on June 2, 2000, which makes the submission of the patent term extension application on August 1, 2000, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

  
Jane A. Axelrad

Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Ginger R. Dreger  
Knobbe, Martens, Olson, & Bear, L.L.P.  
620 Newport Center Drive, 16th Floor  
Newport Beach, CA 92660

6963- 5-2301